Cargando…
Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma
A high-resolution HILIC-MS/MS method was developed to analyze anthranilic acid derivatives of N-glycans released from human serum alpha-1-acid glycoprotein (AGP). The method was applied to samples obtained from 18 patients suffering from high-risk malignant melanoma as well as 19 healthy individuals...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513036/ https://www.ncbi.nlm.nih.gov/pubmed/34641547 http://dx.doi.org/10.3390/molecules26196003 |
_version_ | 1784583137006714880 |
---|---|
author | Virág, Dávid Kremmer, Tibor Lőrincz, Kende Kiss, Norbert Jobbágy, Antal Bozsányi, Szabolcs Gulyás, Lili Wikonkál, Norbert Schlosser, Gitta Borbély, Adina Huba, Zsófia Dalmadi Kiss, Borbála Antal, István Ludányi, Krisztina |
author_facet | Virág, Dávid Kremmer, Tibor Lőrincz, Kende Kiss, Norbert Jobbágy, Antal Bozsányi, Szabolcs Gulyás, Lili Wikonkál, Norbert Schlosser, Gitta Borbély, Adina Huba, Zsófia Dalmadi Kiss, Borbála Antal, István Ludányi, Krisztina |
author_sort | Virág, Dávid |
collection | PubMed |
description | A high-resolution HILIC-MS/MS method was developed to analyze anthranilic acid derivatives of N-glycans released from human serum alpha-1-acid glycoprotein (AGP). The method was applied to samples obtained from 18 patients suffering from high-risk malignant melanoma as well as 19 healthy individuals. It enabled the identification of 102 glycan isomers separating isomers that differ only in sialic acid linkage (α-2,3, α-2,6) or in fucose positions (core, antenna). Comparative assessment of the samples revealed that upregulation of certain fucosylated glycans and downregulation of their nonfucosylated counterparts occurred in cancer patients. An increased ratio of isomers with more α-2,6-linked sialic acids was also observed. Linear discriminant analysis (LDA) combining 10 variables with the highest discriminatory power was employed to categorize the samples based on their glycosylation pattern. The performance of the method was tested by cross-validation, resulting in an overall classification success rate of 96.7%. The approach presented here is significantly superior to serological marker S100B protein in terms of sensitivity and negative predictive power in the population studied. Therefore, it may effectively support the diagnosis of malignant melanoma as a biomarker. |
format | Online Article Text |
id | pubmed-8513036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85130362021-10-14 Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma Virág, Dávid Kremmer, Tibor Lőrincz, Kende Kiss, Norbert Jobbágy, Antal Bozsányi, Szabolcs Gulyás, Lili Wikonkál, Norbert Schlosser, Gitta Borbély, Adina Huba, Zsófia Dalmadi Kiss, Borbála Antal, István Ludányi, Krisztina Molecules Article A high-resolution HILIC-MS/MS method was developed to analyze anthranilic acid derivatives of N-glycans released from human serum alpha-1-acid glycoprotein (AGP). The method was applied to samples obtained from 18 patients suffering from high-risk malignant melanoma as well as 19 healthy individuals. It enabled the identification of 102 glycan isomers separating isomers that differ only in sialic acid linkage (α-2,3, α-2,6) or in fucose positions (core, antenna). Comparative assessment of the samples revealed that upregulation of certain fucosylated glycans and downregulation of their nonfucosylated counterparts occurred in cancer patients. An increased ratio of isomers with more α-2,6-linked sialic acids was also observed. Linear discriminant analysis (LDA) combining 10 variables with the highest discriminatory power was employed to categorize the samples based on their glycosylation pattern. The performance of the method was tested by cross-validation, resulting in an overall classification success rate of 96.7%. The approach presented here is significantly superior to serological marker S100B protein in terms of sensitivity and negative predictive power in the population studied. Therefore, it may effectively support the diagnosis of malignant melanoma as a biomarker. MDPI 2021-10-03 /pmc/articles/PMC8513036/ /pubmed/34641547 http://dx.doi.org/10.3390/molecules26196003 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Virág, Dávid Kremmer, Tibor Lőrincz, Kende Kiss, Norbert Jobbágy, Antal Bozsányi, Szabolcs Gulyás, Lili Wikonkál, Norbert Schlosser, Gitta Borbély, Adina Huba, Zsófia Dalmadi Kiss, Borbála Antal, István Ludányi, Krisztina Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma |
title | Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma |
title_full | Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma |
title_fullStr | Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma |
title_full_unstemmed | Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma |
title_short | Altered Glycosylation of Human Alpha-1-Acid Glycoprotein as a Biomarker for Malignant Melanoma |
title_sort | altered glycosylation of human alpha-1-acid glycoprotein as a biomarker for malignant melanoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513036/ https://www.ncbi.nlm.nih.gov/pubmed/34641547 http://dx.doi.org/10.3390/molecules26196003 |
work_keys_str_mv | AT viragdavid alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT kremmertibor alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT lorinczkende alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT kissnorbert alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT jobbagyantal alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT bozsanyiszabolcs alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT gulyaslili alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT wikonkalnorbert alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT schlossergitta alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT borbelyadina alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT hubazsofia alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT dalmadikissborbala alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT antalistvan alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma AT ludanyikrisztina alteredglycosylationofhumanalpha1acidglycoproteinasabiomarkerformalignantmelanoma |